Literature DB >> 3182320

The salvage of recurrent endometrial carcinoma in the vagina and pelvis.

M G Poulsen1, S J Roberts.   

Abstract

A retrospective analysis was performed on 93 patients who developed recurrent endometrial carcinoma in the pelvis, vaginal vault, and lower 1/3 vagina. There were 12 lower 1/3 vaginal recurrences, 24 vault recurrences and 57 pelvic recurrences from the 1005 patients treated between 1960 and 1976. Median time to recurrence was 30 months. Twenty-six patients had distant metastases also present at the time of recurrence in the sites mentioned above. Thirty-three percent of lower 1/3 vaginal recurrences, 12.5% of vault recurrences, and 5.3% of pelvic recurrences were salvaged with further treatment. The 10-year actuarial survival rates of isolated lower 1/3 vaginal, vaginal vault, and pelvic recurrences were 50%, 45%, and 24% respectively.

Entities:  

Mesh:

Year:  1988        PMID: 3182320     DOI: 10.1016/0360-3016(88)90111-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  2 in total

1.  High-dose rate brachytherapy (HDRB) for primary or recurrent cancer in the vagina.

Authors:  Sushil Beriwal; Dwight E Heron; Robert Mogus; Robert P Edwards; Joseph L Kelley; Paniti Sukumvanich
Journal:  Radiat Oncol       Date:  2008-02-13       Impact factor: 3.481

2.  Use of a Flexible Inflatable Multi-Channel Applicator for Vaginal Brachytherapy in the Management of Gynecologic Cancer.

Authors:  Samuel M Shin; Tamara L Duckworth; Benjamin T Cooper; John P Curtin; Peter B Schiff; J Keith DeWyngaert; Stella C Lymberis
Journal:  Front Oncol       Date:  2015-09-14       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.